Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
about
KIAA0101 interacts with BRCA1 and regulates centrosome numberCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assaySpatial Genome Organization and Its Emerging Role as a Potential Diagnosis ToolBiomarkers in triple negative breast cancer: A reviewThe Interactions of Obesity, Inflammation and Insulin Resistance in Breast CancerBiological markers of invasive breast cancerClinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysisPrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients InvolvedTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinomaControlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responsesHow reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and GynecopathologistsRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based studyImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67Integration of in vivo genotoxicity and short-term carcinogenicity assays using F344 gpt delta transgenic rats: in vivo mutagenicity of 2,4-diaminotoluene and 2,6-diaminotoluene structural isomers.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.A novel model for Ki67 assessment in breast cancer.Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancerUnderstanding the implications of the breast cancer pathology report: a case study.Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Up-regulation of kin17 is essential for proliferation of breast cancerRNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cellsTamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenograftsMTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancerAn ICT infrastructure to integrate clinical and molecular data in oncology research.
P2860
Q24306544-04A0360A-B67B-4F0F-95DA-FC0164C75040Q24337937-20B686E3-AC5B-407C-992E-BD7A1C08E188Q26738275-315A9AA6-C310-429B-AE3E-7788D9084E82Q26775094-1D37C6F6-699A-4DFE-ADF8-BD7DAAD02940Q26777775-897DC082-885F-485F-ADEA-C9E5ED1C8726Q26781177-769B95D3-E45C-44F4-93D8-E7E581907049Q26784351-5184EBD6-E541-499F-88AE-452561B0F99EQ27853207-62296BDC-C8ED-44D3-BDE2-FF31842FDA6DQ28070330-4891DE33-91D7-4A64-8EF0-0D7CE5904ACFQ28085062-3CCEACE1-AACB-489B-98CD-102C5FD363BAQ28085367-B2E3B2B7-1EAD-4DB5-AB91-0416959485DFQ28480895-3DA0CA5D-BE5B-4659-8191-7615215DD397Q28729183-1D7259BD-A2FC-4847-A7A0-350331DF590CQ28730529-E09A3AC0-0549-4CC2-88A2-E1AA25DF83E8Q30543788-DE7A6877-8816-429C-897E-2DEC20FB0457Q30854643-C10B67C5-2565-4EF8-A965-DE9903DC68B5Q33584351-1E6D6112-493F-4069-9584-18C09CD8C20DQ33642280-899DDA69-0350-48DB-B36E-1BDB0F02C705Q33645056-9480296F-FF78-44EC-B464-D025E3E0C19AQ33660598-74B1FA69-A7B4-43C2-8B79-F04C9713F220Q33692020-FB5AA185-E7BB-4324-9A09-9478BD131B05Q33698446-77589E40-605E-448C-BB64-6B8472F6B0B6Q33801255-E102F325-4BCE-46C1-8998-85F4F017103DQ33801758-4B78A2A6-C1CC-4F45-82F3-CED7C20E53D9Q33814616-66A4BACE-22FC-403C-AA12-080D9E6C96AAQ33843751-B52B0F6A-B2E7-432B-94E5-0B87A58CB4AAQ33873665-FDD44A7B-41EA-4F25-B5FC-0237B5BBC40CQ33882536-492DA00C-BC0D-47D6-9B50-8A14646505A0Q33885989-33714122-6E3D-4F04-A31C-282D62BC7F0EQ33915010-FFD35DEF-CEF0-4278-8347-D35B428F275DQ34043118-D3C57918-EB38-47A5-9B21-A7E6F1D47113Q34075234-EF4A55C9-4C06-4DDA-8FA3-4EEE098F7209Q34085163-CC72DC76-B9B0-4708-A762-1D531ABA406EQ34109691-26CDD9F4-6B5F-4BBF-A14E-BD1232EC2971Q34165529-C227F086-D03A-4E5D-A030-FB6D3A567796Q34170606-AC74E7FE-DC81-4DC3-B593-5B908028C5B8Q34177820-86E0427F-CCB0-4B54-9A78-5D95DC9F0A8AQ34203914-80FA0CC7-F0B8-4F7A-A335-1E7DF5EF7952Q34245787-612E76F8-890C-4054-B184-8FDED8BA69C4Q34248060-BCF211A6-CE3A-45D2-BC5D-ED0791327222
P2860
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@ast
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@en
type
label
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@ast
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@en
prefLabel
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@ast
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@en
P2093
P2860
P356
P1476
Ki-67 as prognostic marker in ...... ies involving 12,155 patients.
@en
P2093
C Sotiriou
D Larsimont
E de Azambuja
G de Castro
M J Piccart-Gebhart
M Paesmans
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603756
P407
P577
2007-04-24T00:00:00Z
P5875
P6179
1030523104